Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1853 1
1860 1
1879 1
1885 1
1886 2
1887 1
1888 2
1889 3
1890 1
1891 1
1892 2
1895 1
1896 1
1897 8
1903 2
1906 2
1909 1
1910 2
1911 3
1912 2
1914 2
1915 2
1916 1
1918 1
1919 3
1920 2
1921 2
1922 1
1923 2
1925 1
1926 3
1927 2
1928 3
1929 3
1930 4
1931 5
1932 1
1933 4
1934 1
1936 2
1937 2
1938 2
1939 3
1940 2
1941 1
1945 5
1946 5
1947 11
1948 15
1949 20
1950 34
1951 35
1952 38
1953 18
1954 25
1955 22
1956 11
1957 23
1958 25
1959 23
1960 15
1961 10
1962 15
1963 39
1964 47
1965 64
1966 105
1967 68
1968 79
1969 86
1970 77
1971 63
1972 74
1973 88
1974 97
1975 255
1976 284
1977 230
1978 241
1979 287
1980 300
1981 307
1982 396
1983 404
1984 460
1985 463
1986 471
1987 523
1988 582
1989 677
1990 709
1991 732
1992 672
1993 747
1994 770
1995 777
1996 918
1997 926
1998 930
1999 1039
2000 1368
2001 1398
2002 1529
2003 1563
2004 1751
2005 2007
2006 2079
2007 2155
2008 2251
2009 2393
2010 2553
2011 2768
2012 2983
2013 3187
2014 3990
2015 4260
2016 4413
2017 4644
2018 5626
2019 6223
2020 7101
2021 7909
2022 8998
2023 9624
2024 2867

Text availability

Article attribute

Article type

Publication date

Search Results

99,998 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Yaye-Awa
Page 1
The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
Zhou Y, Zhi H, Teng Y. Zhou Y, et al. J Med Virol. 2023 Jan;95(1):e28138. doi: 10.1002/jmv.28138. Epub 2022 Sep 21. J Med Virol. 2023. PMID: 36097349 Free PMC article. Review.
As of August 2022, Omicron is classified into five main lineages, BA.1, BA.2, BA.3, BA.4, BA.5 and some sublineages (BA.1.1, BA.2.12.1, BA.2.11, BA.2.75, BA.4.6) (https://www.gisaid.org/). ...Recently, global s …
As of August 2022, Omicron is classified into five main lineages, BA.1, BA.2, BA.3, BA.4, BA.5 and some s …
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Kimura I, et al. Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14. Cell. 2022. PMID: 36198317 Free PMC article.
After the global spread of the SARS-CoV-2 Omicron BA.2, some BA.2 subvariants, including BA.2.9.1, BA.2.11, BA.2.12.1, BA.4, and BA.5, emerged in multiple countries. ...Cell culture experiments showed that BA.2.12.1 and B
After the global spread of the SARS-CoV-2 Omicron BA.2, some BA.2 subvariants, including BA.2.9.1, BA.2.11, B
Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
Kumar S, Karuppanan K, Subramaniam G. Kumar S, et al. J Med Virol. 2022 Oct;94(10):4780-4791. doi: 10.1002/jmv.27927. Epub 2022 Jun 16. J Med Virol. 2022. PMID: 35680610 Free PMC article.
We used computational tools to assess the spike infectivity, transmission, and pathogenicity of Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) in this study. BA.1 has 39 mutations, BA.1.1 has 40 mutations, BA.2 has 31 mut …
We used computational tools to assess the spike infectivity, transmission, and pathogenicity of Omicron (BA.1) and sub-variants (B
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Kitchin N; C4591031 Clinical Trial Group. Winokur P, et al. N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082. N Engl J Med. 2023. PMID: 36652353 Free PMC article. Clinical Trial.
Exploratory analyses assessed immune responses against omicron BA.4, BA.5, and BA.2.75 subvariants. RESULTS: A total of 1846 participants underwent randomization. ...BA.4-BA.5 and BA.2.75 neutralizing titers were numerically higher with 3 …
Exploratory analyses assessed immune responses against omicron BA.4, BA.5, and BA.2.75 subvariants. RESULTS: A total of …
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X. Cao Y, et al. Cell Host Microbe. 2022 Nov 9;30(11):1527-1539.e5. doi: 10.1016/j.chom.2022.09.018. Epub 2022 Oct 4. Cell Host Microbe. 2022. PMID: 36270286 Free PMC article.
Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76, and BA.5 in India. ...Relative to BA.4/BA.5, BA.2.75 exhibits reduced evasion of humoral immunity from BA
Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76 …
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, Cele S, Lustig G, Amoako D, Wolter N, Samsunder N, Sivro A, San JE, Giandhari J, Tegally H, Pillay S, Naidoo Y, Mazibuko M, Miya Y, Ngcobo N, Manickchund N, Magula N, Karim QA, von Gottberg A, Abdool Karim SS, Hanekom W, Gosnell BI; COMMIT-KZN Team; Lessells RJ, de Oliveira T, Moosa MS, Sigal A. Khan K, et al. Nat Commun. 2022 Aug 10;13(1):4686. doi: 10.1038/s41467-022-32396-9. Nat Commun. 2022. PMID: 35948557 Free PMC article.
In BA.1-infected unvaccinated individuals, neutralization relative to BA.1 declines 7.6-fold for BA.4 and 7.5-fold for BA.5. ...The fold-drop versus ancestral virus neutralization in this group is 4.0-fold for BA.1, 12.9-fold for BA.4, an …
In BA.1-infected unvaccinated individuals, neutralization relative to BA.1 declines 7.6-fold for BA.4 and 7.5-fold for …
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
Zou J, Kurhade C, Xia H, Liu M, Xie X, Ren P, Shi PY. Zou J, et al. Nat Commun. 2022 May 26;13(1):2956. doi: 10.1038/s41467-022-30580-5. Nat Commun. 2022. PMID: 35618703 Free PMC article.
Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in late January 2020). The BA.1-infected sera neutralize BA.1, BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geomet …
Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in …
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, Kandeil A, Pekosz A, Chan KC, Tsang LC, Ko FW, Chen C, Yiu K, Luk LL, Chan KK, Webby RJ, Poon LL, Hui DS, Peiris M. Cheng SS, et al. J Clin Virol. 2022 Nov;156:105273. doi: 10.1016/j.jcv.2022.105273. Epub 2022 Aug 31. J Clin Virol. 2022. PMID: 36081282 Free PMC article.
BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11.0). CONCLUSIONS: BA.4 and BA.5 subvariants were less susceptible to BNT162b2 or CoronaVac vaccine elicited antibody neutraliz
BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Muik A, Lui BG, Bacher M, Wallisch AK, Toker A, Finlayson A, Krüger K, Ozhelvaci O, Grikscheit K, Hoehl S, Ciesek S, Türeci Ö, Sahin U. Muik A, et al. Sci Immunol. 2022 Nov 25;7(77):eade2283. doi: 10.1126/sciimmunol.ade2283. Epub 2022 Nov 18. Sci Immunol. 2022. PMID: 36125366 Free PMC article.
BNT162b2-vaccinated individuals after Omicron BA.1 breakthrough infection have strong serum-neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 variants of concern (VOCs) yet less against the highly contagious Omicron sublineages BA
BNT162b2-vaccinated individuals after Omicron BA.1 breakthrough infection have strong serum-neutralizing activity against Omicron …
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.
Rössler A, Netzl A, Knabl L, Schäfer H, Wilks SH, Bante D, Falkensammer B, Borena W, von Laer D, Smith DJ, Kimpel J. Rössler A, et al. Nat Commun. 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3. Nat Commun. 2022. PMID: 36513653 Free PMC article.
Several studies have shown that SARS-CoV-2 BA.1 omicron is an immune escape variant. Meanwhile, however, omicron BA.2 and BA.5 became dominant in many countries and replaced BA.1. As both have several mutations compared to BA.1, we analyzed whet …
Several studies have shown that SARS-CoV-2 BA.1 omicron is an immune escape variant. Meanwhile, however, omicron BA.2 and B
99,998 results
You have reached the last available page of results. Please see the User Guide for more information.